
|Videos|September 23, 2020
FDA-approved Therapies for Relapsed/Refractory HER2+ mBC
Advertisement
Challenges for patients diagnosed with metastatic HER2+ breast cancer and recent FDA approved-therapies for the third-line setting are reviewed.
Advertisement
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Capivasertib Plus Abiraterone and Prednisone for PTEN-Deficient mHSPC
2
Luspatercept Misses Primary RBC-TI End Point But Shows Clinically Meaningful Improvement for Anemia in Myelofibrosis
3
MONUMENTAL-3 Data Support Talquetamab Plus Daratumumab ± Pomalidomide as a New SOC in R/R Myeloma
4
CLL14 Final Analysis Shows Long-Term PFS Gain With Venetoclax/Obinutuzumab in Previously Untreated CLL
5











































































